BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Accomplishes Multiple Important Milestones in 2018
In 2018, BriaCell obtained topline safety and efficacy clinical data, achieved proof of concept and advanced its clinical program The company initiated patient dosing in a phase I/IIa clinical trial of its breast cancer immunotherapy Bria-IMT in combination with immune checkpoint inhibitors KEYTRUDA or YERVOY BriaCell is also working on the development of a personalized off-the-shelf immunotherapy treatment for advanced breast cancer that will potentially reduce the cost of tailor-made immunotherapy BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focused on immuno-oncology, recently announced the completion of several important milestones in 2018. These include obtaining topline safety and efficacy…